Together, these considerations highlight the need for studies in tumor-bearing models with sex-balanced cohorts and direct biochemical evaluation of the ASMase/ceramide–ROS pathway to fully establish the therapeutic potential and clinical translatability of NACA as a radioprotective agent. This evidence concerns the gene NACA and neoplasm.